This trial is active, not recruiting.

Condition breast cancer survivors
Treatment survey
Sponsor Abramson Cancer Center of the University of Pennsylvania
Start date July 2014
End date April 2016
Trial size 40 participants
Trial identifier NCT02753985, UPCC 15114


This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. Both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. The target number of subjects is 64 (32 patients and 32 partners). The primary method of data collection will be face-to-face semi-structured interviews. These interviews will be audio-recorded.

United States Pennsylvania
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Number of Surveys Completed
time frame: 2 years

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Women and partners of women with stage I-III breast cancer who 1. have completed primary cancer treatments (surgery, chemotherapy, radiotherapy) 2. have experienced AI side effects 3. live with a romantic partner. Exclusion Criteria:

Additional Information

Official title Adherence to Aromatase Inhibitors: The Role of Partners
Principal investigator Jun Mao, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Abramson Cancer Center of the University of Pennsylvania.